Home » Entries posted by pharmanewsdaily
Entries posted by pharmanewsdaily
Merck to acquire coronavirus vaccine candidate developer Themis Bioscience

Merck to acquire coronavirus vaccine candidate developer Themis Bioscience

Merck acquisition of Themis Bioscience : Merck has signed a deal to acquire Themis Bioscience, an Austrian vaccine developer for an undisclosed price with an objective to gain access to the latter’s coronavirus vaccine candidate. Themis Bioscience by leveraging its measles virus vector platform has developed a pipeline of vaccine candidates and immune-modulatory therapies. Recently, […]

Dupixent delivers positive results in eosinophilic esophagitis trial

Regeneron Pharmaceuticals and Sanofi said that their co-developed eczema drug Dupixent (dupilumab) has met the co-primary endpoints of Part A of a phase 3 trial in patients 12 years and older who have eosinophilic esophagitis (EoE). The late-stage trial also all the key secondary endpoints. Dupixent is now the first and only biologic to demonstrate […]

Continue reading …
Roche acquires DNA sequencing technology company Stratos Genomics

Roche acquisition of Stratos Genomics : Swiss pharma giant Roche has acquired US-based early-stage DNA sequencing technology company Stratos Genomics for an undisclosed price. The transaction is expected to help Roche advance the development of its nanopore sequencer through the access to Sequencing by Expansion (SBX), Stratos Genomics’ unique chemistry. Roche said that once developed, […]

Continue reading …
Nevro’s Senza Omnia SCS system gets CE mark for chronic pain treatment

US medical device company Nevro has secured CE mark approval for its Senza Omnia spinal cord stimulation system (Senza Omnia SCS system) for delivering its HF10 therapy for the treatment of chronic pain. The Omnia system is a new spinal cord stimulation (SCS) platform, which is said to consist of many new components like the […]

Continue reading …
Cipla gets FDA’s final approval for generic version of Migranal with CGT designation

Cipla has secured final approval for its abbreviated new drug application (ANDA) for Dihydroergotamine Mesylate Nasal Spray 4mg/mL from the US Food and Drug Administration (FDA) with a competitive generic therapy (CGT) designation. The Indian pharma company said that it is the first approved applicant for such CGT and as a result is eligible for […]

Continue reading …
Comet Bio reports positive results for prebiotic Arrabina

Comet Bio said that Arrabina, its arabinoxylan plant fiber extract, has delivered positive clinical trial results with its gastrointestinal (GI) tolerability no different than placebo. The results are from a completed randomized, placebo-controlled, crossover clinical trial that assessed the gastrointestinal tolerability and prebiotic effects of Arrabina. Comet Bio said that results show that consumers can take […]

Continue reading …
Quidel’s Lyra Direct SARS-CoV-2 Assay gets FDA EUA status for molecular detection of COVID-19

Quidel has been given emergency use authorization from the US Food and Drug Administration (FDA) for its Lyra Direct SARS-CoV-2 Assay to be used for the molecular detection of COVID-19. According to the diagnostic healthcare products manufacturer, the EUA status enables the Lyra Direct SARS-CoV-2 Assay for carrying out direct sample processing without the extraction […]

Continue reading …
Coronavirus vaccine trial results : Moderna mRNA-1273 shows early promise

Moderna said that mRNA-1273, its novel coronavirus vaccine candidate, has delivered positive interim data in a phase 1 clinical trial by eliciting neutralizing antibody titer levels in all eight initial participants across the 25 µg and 100 µg dose cohorts. The early-stage clinical trial in humans was led by the US National Institute of Allergy […]

Continue reading …
Takeda gets extended EC approval for ADCETRIS in sALCL

Takeda Pharmaceutical has secured extended approval for ADCETRIS (brentuximab vedotin) in the European Union to include the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL) in adult patients. The approval from the European Commission (EC) is for the combination of ADCETRIS with CHP (cyclophosphamide, doxorubicin, prednisone. It comes in the wake of a […]

Continue reading …
Gesynta Pharma reports positive results for GS-248 phase 1 study

Swedish pharma company Gesynta Pharma has reported positive results from the phase 1 clinical trial of GS-248, which is being developed for the treatment of microvascular diseases in chronic inflammatory conditions. The purpose of the early-stage clinical trial was to assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of GS-248 after subjecting healthy subjects to […]

Continue reading …
Page 1 of 117123Next ›Last »